REFRACTORY CLASSIC HODGKIN LYMPHOMA
Clinical trials for REFRACTORY CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control TerminatedThis phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HIV cancer hope: immune combo shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC